Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes (Q37320957)

19 August 2017

Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes (English)

1 reference

19 August 2017

0 references

1 reference

Mee Kyoung Kim

1

1 reference

19 August 2017

Seung-Hyun Ko

2

1 reference

19 August 2017

Ki-Hyun Baek

3

1 reference

19 August 2017

Yu-Bae Ahn

4

1 reference

19 August 2017

Kun-Ho Yoon

5

1 reference

19 August 2017

Moo-Il Kang

6

1 reference

19 August 2017

Kwang-Woo Lee

7

1 reference

19 August 2017

Ki-Ho Song

8

1 reference

19 August 2017

26 August 2009

1 reference

The Korean journal of internal medicine

19 August 2017

1 reference

19 August 2017

24

1 reference

19 August 2017

3

1 reference

19 August 2017

227-232

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

1 January 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Standards of medical care in diabetes--2006

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Nonalbuminuric renal insufficiency in type 2 diabetes.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Rosiglitazone reduces urinary albumin excretion in type II diabetes

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

The 10-year incidence of renal insufficiency in people with type 1 diabetes.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2732782

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19721859

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19721859

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3904/KJIM.2009.24.3.227

1 reference

19 August 2017

1 reference

19 August 2017

1 reference